drugset / Trial / NCT03838367
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).
Timeline
- Start
- 2019-04-22
- Primary completion
- 2022-07-15
- Completion
- 2022-09-16
Outcome
Outcome not reported
Stopped (Business): “Study terminated prematurely due to business reasons. Participants are no longer examined or receiving intervention.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leronlimab | Monoclonal antibody | 350 mg | Subcutaneous |
| Subject | Leronlimab | Monoclonal antibody | 525 mg | Subcutaneous |
| Subject | Leronlimab | Monoclonal antibody | 700 mg | Subcutaneous |
| Background | Carboplatin | Small molecule | — | Intravenous |